Literature DB >> 7044652

Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin.

H Witzgall, F Hirsch, B Scherer, P C Weber.   

Abstract

1. The acute haemodynamic and hormonal effects of 100 mg of captopril (SQ 14.225) orally were tested in twelve healthy men in the sodium replete state before and after indomethacin pretreatment. 2. Without indomethacin, mean arterial blood pressure was reduced at 30 and 60 min after captopril (P less than 0.02). Heart rate did not change during the whole experiment. Although plasma renin activity (PRA) increased (P less than 0.002), plasma and urinary aldosterone and plasma 18-hydroxycorticosterone (18-OH-B) decreased after captopril (P less than 0.02). Prostaglandin (PG) E2, sodium and potassium excretion rates remained constant after captopril. 3. Under indomethacin pretreatment, the fall in mean arterial blood pressure was less than without indomethacin at 30 and 60 min after captopril (P less than 0.05). Heart rate was constantly lower than without indomethacin during the whole experiment (P less than 0.05). Indomethacin pretreatment decreased basal PGE2 excretion (P less than 0.02) and baseline PRA as well as the increase in PRA after captopril (P less than 0.05). Control mineralocorticoid levels were significantly lower than without indomethacin. In indomethacin-pretreated subjects, aldosterone did not further decrease after captopril, and 18-OH-B fell only slightly. 4. Without indomethacin pretreatment a significant, positive correlation was found between PRA values before captopril and the maximum decrease of mean arterial blood pressure after captopril. Under indomethacin pretreatment this correlation was no longer demonstrable. The results suggest that prostaglandins may contribute to the haemodynamic and hormonal actions of captopril.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7044652     DOI: 10.1042/cs0620611

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.

Authors:  P A Van Zwieten; A De Jonge; P B Timmermans
Journal:  Pharm Weekbl Sci       Date:  1983-10-21

3.  Arachidonic acid metabolites, hypertension and arteriosclerosis.

Authors:  P C Weber; W Siess; B Scherer; E Held; H Witzgall; R Lorenz
Journal:  Klin Wochenschr       Date:  1982-05-17

Review 4.  Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients?

Authors:  K Radack; C Deck
Journal:  J Gen Intern Med       Date:  1987 Mar-Apr       Impact factor: 5.128

Review 5.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 6.  Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure.

Authors:  K Chatterjee; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

7.  Studies on the effect of two angiotensin-converting enzyme inhibitors, captopril and cilazapril, on platelet and vascular prostaglandin metabolism in vivo.

Authors:  B Wagner; H G Eichler; B Schneider; B Blöchl-Daum; B Brenner; S Gasic; K Lechner; P A Kyrle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

Review 8.  [Eicosanoids and phospholipases].

Authors:  M Goerig; A J Habenicht; G Schettler
Journal:  Klin Wochenschr       Date:  1985-04-01

Review 9.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.